InvestSMART

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $10.270 -1.14 (-9.99%)+
Announcement
Release
26 Feb 2026 9:58AM
Price at Release
$11.410
Full Release
download
Summary
Clinuvel Pharmaceuticals Limited reported its half-year results for the period ending December 31, 2025. The company maintained underlying profitability with revenues of AUD 36.93 million, a 4% increase from the previous year, and a profit after tax of AUD 10.44 million, which marked a 26% decrease. The report highlights significant advancements in their business model, focusing on long-term safety through the development of melanocortins and controlled-release injectable peptides. The company has also validated the manufacturing process for NEURACTHEL® and is engaged in ongoing Phase III studies for vitiligo. Clinuvel aims to expand its market presence with strategic preparations for the U.S. vitiligo market, targeting significant market penetration within the first two years. The balance sheet reflects strong cash reserves of AUD 233 million, supporting the company's self-financing expansion and continued pipeline development.
Key Points
  • Maintained underlying profitability with AUD 36.93 million in revenues.
  • Profit after tax decreased by 26% to AUD 10.44 million.
  • Focus on long-term safety with melanocortins and injectable peptides.
  • Ongoing Phase III studies for vitiligo.
  • Strategic preparation for U.S. vitiligo market expansion.
  • Strong cash reserves of AUD 233 million for self-financing expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.